News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
2,980 Results
Type
Article (358)
Company Profile (1)
Press Release (2621)
Section
Business (1010)
Career Advice (11)
Deals (141)
Drug Delivery (6)
Drug Development (693)
FDA (98)
Job Trends (156)
News (1921)
Policy (189)
Tag
2027 Pharm Country Standard (1)
Academia (4)
Alliances (368)
Alzheimer's disease (4)
Antibody-drug conjugate (ADC) (59)
Approvals (104)
Artificial intelligence (6)
Best Places to Work (126)
Biosimilars (3)
Bladder cancer (3)
Breast cancer (70)
Cancer (153)
Cardiovascular disease (4)
Career advice (8)
CAR-T (1)
Cell therapy (2)
Clinical research (643)
Collaboration (14)
Complete response letters (3)
COVID-19 (5)
C-suite (3)
Data (43)
Diabetes (1)
Diagnostics (16)
Digital health (1)
Drug discovery (2)
Drug pricing (5)
Drug shortages (1)
Duchenne muscular dystrophy (1)
Earnings (339)
Editorial (2)
Events (320)
Executive appointments (5)
FDA (122)
Funding (2)
Generative AI (2)
Gene therapy (3)
GLP-1 (7)
Government (14)
Healthcare (30)
Immunology and inflammation (1)
Immuno-oncology (2)
Infectious disease (6)
Inflation Reduction Act (1)
Intellectual property (1)
Interviews (1)
IPO (52)
IRA (1)
Job creations (31)
Job search strategy (8)
JPM (1)
Labor market (1)
Layoffs (5)
Legal (41)
Liver cancer (1)
Lung cancer (48)
Lymphoma (2)
Machine learning (1)
Manufacturing (6)
Medical device (8)
Medtech (8)
Mergers & acquisitions (88)
Metabolic disorders (4)
Neurodegenerative disease (1)
Neuroscience (4)
NextGen: Class of 2026 (15)
Non-profit (12)
Now hiring (14)
Obesity (3)
Opinion (8)
Ovarian cancer (9)
Pain (1)
Patents (4)
Patient recruitment (2)
People (275)
Pharmaceutical (1)
Phase 1 (157)
Phase 2 (219)
Phase 3 (330)
Pipeline (31)
Policy (2)
Postmarket research (34)
Preclinical (23)
Prostate cancer (2)
Psychedelics (1)
Radiopharmaceuticals (2)
Rare diseases (4)
Real estate (12)
Regulatory (181)
Research institute (11)
Resumes & cover letters (1)
RSV (1)
Schizophrenia (1)
Series A (1)
Special edition (1)
Sponsored (1)
Startups (14)
Stomach cancer (4)
Tariffs (2)
The Weekly (4)
Vaccines (3)
Weight loss (3)
Date
Last 7 days (3)
Last 30 days (13)
Last 365 days (150)
2026 (22)
2025 (157)
2024 (166)
2023 (139)
2022 (330)
2021 (229)
2020 (198)
2019 (198)
2018 (129)
2017 (167)
2016 (102)
2015 (123)
2014 (101)
2013 (68)
2012 (77)
2011 (125)
2010 (106)
Location
Africa (4)
Arizona (2)
Asia (561)
Australia (42)
California (18)
Canada (11)
China (2)
Colorado (2)
Delaware (28)
Europe (453)
Florida (2)
Illinois (5)
Indiana (1)
Japan (48)
Maryland (2)
Massachusetts (9)
New Jersey (78)
New York (7)
Northern California (11)
Ohio (1)
Pennsylvania (2)
South America (5)
Southern California (2)
Texas (1)
United States (147)
Utah (1)
Virginia (1)
Washington D.C. (1)
Washington State (1)
Wisconsin (2)
2,980 Results for "daiichi sankyo".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified pyrrolobenzodiazepine payload.
February 3, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
January 22, 2026
·
3 min read
Lung cancer
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd
According to analysts, the new data could present a path to accelerated approval for ifinatamab deruxtecan, a product of Merck and Daiichi Sankyo’s troubled ADC partnership.
September 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
January 21, 2026
·
3 min read
Press Releases
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
January 8, 2026
·
5 min read
Press Releases
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
February 5, 2026
·
5 min read
Press Releases
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
January 7, 2026
·
4 min read
Approvals
AstraZeneca, Daiichi Sankyo Move Enhertu to First-Line Metastatic Breast Cancer
Analysts at Jefferies called the approval “highly significant,” estimating it could add $2 billion to $3 billion to peak Enhertu sales.
December 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo Establishes Third Research Institute in San Diego
October 2, 2025
·
1 min read
Press Releases
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
December 9, 2025
·
13 min read
1 of 298
Next
